Key result
CVD death rates in breast cancer survivors fell ~1.8% annually from 1999 to 2020.
Why the study?
Previous studies calculating CVD-related death rates among breast cancer survivors used the general US female population as the denominator, which may have produced misleading comparisons.
Observational
Using a disease-specific denominator reveals that CVD-related death rates among breast cancer survivors are substantially higher than the general population, correcting previous methodological underestimates and highlighting the need for targeted cardio-oncology care.
Answers are grounded in this paper and cite their sources.
Survivor-specific denominators unmask elevated CVD mortality in breast cancer survivors; extends prior observational estimates and supports targeted cardio-oncology research.
Breast cancer is the most common cancer among women in the United States, and cardiovascular disease (CVD) is a leading cause of death in this population. Understanding CVD-related death among breast cancer survivors is critical to inform policies. Previous studies calculating CVD-related death rates in this population used data from the Centers for Disease Control and Prevention (CDC) Wide-ranging ONline Data for Epidemiologic Research (WONDER) with the general US female population as the denominator, which may have produced misleading comparisons. For example, age-adjusted CVD-related death rates have appeared lower among women with breast cancer than in the general US female population, despite survivors facing an elevated CVD risk, understating the need for CVD-focused survivorship care. We demonstrated 2 methodologically appropriate approaches for estimating CVD-related death rates among US women with breast cancer from 1999 through 2020, using a denominator restricted to the breast cancer survivor population, derived from Surveillance, Epidemiology, and End Results (SEER) and Projected Prevalence (ProjPrev) data. We found trends in CVD-related death rates that were broadly consistent with previous studies, with an average annual percentage change of −1.8 (95% CI, −2.0 to −1.6). Our estimates were more intuitive than those from previous studies because they correctly reflected an elevated, rather than reduced, risk relative to the general population: the age-adjusted CVD-related death rate per 100 000 women with breast cancer was 1078.1 in 1999 and 733.1 in 2020. These findings suggest that our approaches can be applied to future research on cause-specific mortality among patients with cancer using CDC WONDER data. Future studies may improve generalizability and identify strategies for linking databases to generate more accessible evidence for public health decision-making.
No takes yet. Share an insight, caveat, or question.
Le et al. (2026) conducted an observational in Breast cancer and cardiovascular disease. Breast cancer survivor population denominator vs. General US female population denominator was evaluated on Average annual percentage change (AAPC) in age-adjusted CVD-related death rates (AAPC -1.8, 95% CI -2.0 to -1.6). Using a breast cancer survivor denominator, the age-adjusted CVD-related death rate per 100,000 women with breast cancer was 1078.1 in 1999 and 733.1 in 2020, with an AAPC of -1.8.
Synapse has enriched 10 related papers. Consider them for comparative context: